WO2021260636A1 - A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract - Google Patents
A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract Download PDFInfo
- Publication number
- WO2021260636A1 WO2021260636A1 PCT/IB2021/055647 IB2021055647W WO2021260636A1 WO 2021260636 A1 WO2021260636 A1 WO 2021260636A1 IB 2021055647 W IB2021055647 W IB 2021055647W WO 2021260636 A1 WO2021260636 A1 WO 2021260636A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carnosine
- pharmaceutical composition
- derivatives
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
- 239000009429 Ginkgo biloba extract Substances 0.000 title claims abstract description 44
- 229940068052 ginkgo biloba extract Drugs 0.000 title claims abstract description 44
- 235000020686 ginkgo biloba extract Nutrition 0.000 title claims abstract description 44
- 229940044199 carnosine Drugs 0.000 title description 14
- 108010087806 Carnosine Proteins 0.000 claims abstract description 65
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 65
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 58
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 238000013270 controlled release Methods 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 16
- 238000013265 extended release Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 8
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 244000194101 Ginkgo biloba Species 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000008100 Ginkgo biloba Nutrition 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229930184727 ginkgolide Natural products 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960000540 polacrilin potassium Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 description 1
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 1
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
Definitions
- the present invention relates to a pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
- the present invention relates to a pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
- the present invention relates to a controlled release pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
- Oxidative stress, ion balance and pH balance are some the most critical factors involved in the major acute and chronic physiological imbalance.
- the depletion of powerful antioxidant renders cells particularly vulnerable to oxidative stress.
- the resulting damage is the key step in the onset and progression of many disease states.
- Degenerative nerve diseases relates to progressive damage to the neurons in the nervous system.
- Several nervous disorder includes Alzheimer's disease (AD), Parkinson's disease (PD), Dementia and so on.
- AD Alzheimer's disease
- PD Parkinson's disease
- Dementia Dementia
- endogenous and exogenous compound are known to protect against oxidative stress and apoptosis. These endogenous and exogenous compound are helpful in management and prevention of degenerative nerve diseases.
- L-Carnosine is used as protective agent for many therapies. Ginkgo Biloba extract reduces oxidative damage and stimulates cell survival. While both these compounds are known to be administrated individually for their respective mechanism of action, administration with immediate release has a limitation of multiple daily administration leading to fluctuating plasma concentrations.
- composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one or both active ingredient are in controlled release form, are not known.
- the present invention relates to pharmaceutical composition comprising L- Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
- the present invention relates to pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
- the present invention relates to a controlled release pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
- the active ingredient as per present invention are used in therapeutically effective amount.
- “Therapeutically effective amount” or “effective amount” refers to the amount of a pharmaceutically active agent when administered, is sufficient to affect such prevention or treatment.
- the therapeutically effective amount will vary depending on the disease and its severity, and the age, weight, and other conditions of the patient to be treated.
- pharmaceutical compositions herein refers to any composition for administration to human or animal by any route and includes but are not limited to delayed release, extended release and pulsed-release.
- immediate release refers to any composition for administration to human or animal which releases active ingredient upon administration immediately.
- controlled release refers to any composition for administration to human or animal which is not immediate release and includes extended release, delayed release and pulsatile release.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form.
- the present invention relates to a pharmaceutical composition consisting of a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
- the present invention relates to a controlled release pharmaceutical composition
- a controlled release pharmaceutical composition comprising c. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and d. Ginkgo Biloba extract.
- the present invention relates to a controlled release pharmaceutical composition consisting of c. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and d. Ginkgo Biloba extract.
- the present invention relates to a pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein at least one active ingredient is in controlled release form.
- the present invention relates to a pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form.
- the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein at least one active ingredient is in controlled release form.
- the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition is a bilayer tablet.
- the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition comprises comprises Hydroxy Propyl Methyl cellulose as extended release polymer.
- the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b.
- Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition releases less than 90% L-Carnosine or pharmaceutically acceptable salts or derivatives thereof after 8 hours in 6.8 pH phosphate buffer.
- the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in extended release form and wherein said composition is a bilayer tablet.
- the present invention relates to a controlled release pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg.
- the present invention relates to a controlled release oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg.
- a pharmaceutical composition as per present invention includes delayed release, extended release, pulsatile release or combination thereof.
- a pharmaceutical composition as per present invention comprises active ingredients in homogenous mixture or physically separated compartments.
- a pharmaceutical composition as per present invention comprises L-Carnosine or pharmaceutically acceptable salts or derivatives thereof are in extended release form.
- a pharmaceutical composition as per present invention includes for oral, intravenous or other routes of administration.
- a pharmaceutical composition as per present invention includes solid, liquid, semisolid or other dosage forms.
- the present invention also relates to a process for preparation of a pharmaceutical composition wherein said process comprises step of a. Preparing granules of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof with at least one controlled release excipient, b. Preparing granules of Ginkgo Biloba extract, c. Processing granules of step (a) and step (b) into bilayer tablet.
- a process as per present invention involves non aqueous solvent granulation.
- Carnosine is an endogenous dipeptide, composed of b-alanine and L- histidine. Carnosine has pH-buffering, metal-ion chelation, and antioxidant capacity as well as the capacity to protect against formation of advanced glycation and lipoxidation end-products. Carnosine is found naturally mainly in the skeletal muscles, central nervous system, olfactory neurons and in the lens of the eye in some vertebrates, including humans.
- carnosine may be involved in the prevention and therapy of oxidative driven disorders, including neurodegenerative diseases and hypoxic-ischemic damage of CNS.
- Carnosine treatment has been reported to improve glucose metabolism as well as spatial recognition memory, retention and recall. It has also been reported to have pronounced neuroprotective action on Parkinson’s disease increasing efficiency of basic therapy and suppressing beta amyloid peptide toxicity in Alzheimer’s disease.
- L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in the equivalent therapeutically effective amount of L-Carnosine. In a preferred embodiment, L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in an amount equivalent to 50mg to 400mg of L-Camosine.
- Ginkgo Biloba is the leaf extract primarily for China. It has antioxidant, anti-apoptotic, anti-ageing properties. In ancient and modem Chinese herbal pharmacopoeia, it is indicated for treatment for heart and lung complications. In US and Europe, it is used for its protective effect on neuron in de-generative dementias of the Alzheimer type. Dementia is a chronic or progressive condition characterized by impaired cognitive capacity.
- Ginkgo Biloba Extract mainly contains 22.0 - 27.0% flavonoids, calculated as flavonoid glycosides and terpenoids, terpenoids consisting of bilobalide and the ginkgolides (2.6 - 3.2% bilobalide and 2.8 - 3.4% ginkgolides A, B and C).
- terpenoids consisting of bilobalide and the ginkgolides (2.6 - 3.2% bilobalide and 2.8 - 3.4% ginkgolides A, B and C).
- Usually administered doses of Ginkgo Biloba extract is 120-240 mg/day divided into 2 or 3 doses with meals. It has time to peak plasma concentration (Tmax) of 1 to 2 hours and shorter plasma half-life of ginkgolide A (3 to 4 hours) and B (4 to 6 hours) and bilobalide (2 to 3 hours) with primary excreted in the urine unchanged. Multiple daily doses lead to non-uniform plasma levels of its content in the body.
- Ginkgo Biloba Extract is in an amount of 20 mg to 200 mg.
- L-Carnosine is the antioxidant with neuroprotective effect through involvement in endogenous pathway.
- Gingko biloba extract is a herbal exogenous antiapoptotic agent with directly neuroprotective effect.
- the present invention relates to a pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
- the present invention relates to a controlled release pharmaceutical composition comprising L- Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
- the pharmaceutical composition as per present invention contains Ginkgo Biloba extract and L-Carnosine in the ratio between 1:1 and 1:6. In one embodiment, the pharmaceutical composition as per present invention contains Ginkgo Biloba extract and L-Camosine in an amount of 60mg;200mg, 90mg;300mg and 120mg; 400mg.
- the pharmaceutical compositions are the different type of medicinal preparation designed for the administration of targeted one or more drugs.
- the pharmaceutical compositions as per present invention includes immediate release, delayed release, extended release and pulsed-release.
- the pharmaceutical compositions can be prepared using uniform mixture of two or more drugs.
- pharmaceutical composition can be prepared with one or more drugs in separate compartment within a single dosage form.
- the pharmaceutical compositions as per present invention can be administered by oral, intravenous or other routes of drug administration.
- the pharmaceutical compositions as per present invention can be solid, liquid, semisolid or any other dosage form.
- the pharmaceutical compositions as per present invention can be prepared as one or more drug in modified release and other drugs as immediate release in single dosage form.
- the oral pharmaceutical dosage form are tablets, capsules, suspensions, powders and granules, multi-particulate dosage forms and the likes.
- the multicompartment dosage form are bilayer tablets, capsule-in-capsule, tablet-in capsule and any other dosage form.
- the pharmaceutical compositions can be formulated by any techniques known to or appreciated by a person skilled in the art
- the controlled release excipients as per present invention includes enteric polymer, sustained release polymers, natural polysaccharides, wax.
- the representative controlled release agents are hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, polyethylene glycol, sodium alginate and so on.
- the oral pharmaceutical composition further includes optionally any one or a combination of one or more pharmaceutically acceptable excipients, such as but not limited to carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants and solubility enhancers.
- Each film coated bilayer tablet Contains: Ginkgo biloba 60 mg (as immediate release form) and L-Camosine 200 mg (as sustained release form)
- Sift Crospovidone (XL- 10, Colloidal Silicon di oxide, Polacrilin Potassium and Sodium stearyl fumarate through 40# mesh sieve and collect into a poly bag Transfer the 20# mesh dried sifted granules into the blender and add the total sifted (40 # mesh) quantity of Crospovidone (XL- 10), Colloidal Silicon di oxide, Polacrilin Potassium and Sodium stearyl fumarate into the blender and mix for 15min at 10 RPM.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract. The present invention relates to pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form. The present invention relates to a controlled release pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
Description
A PHARMACEUTICAL COMPOSITION COMPRISING L-CARNOSINE AND GINKGO BILOBA EXTRACT.
The present invention relates to a pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract. The present invention relates to a pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form. The present invention relates to a controlled release pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
BACKGROUND OF INVENTION
Oxidative stress, ion balance and pH balance are some the most critical factors involved in the major acute and chronic physiological imbalance. The depletion of powerful antioxidant renders cells particularly vulnerable to oxidative stress. The resulting damage is the key step in the onset and progression of many disease states.
Degenerative nerve diseases relates to progressive damage to the neurons in the nervous system. Several nervous disorder includes Alzheimer's disease (AD), Parkinson's disease (PD), Dementia and so on. Several endogenous and exogenous compound are known to protect against oxidative stress and apoptosis. These endogenous and exogenous compound are helpful in management and prevention of degenerative nerve diseases.
L-Carnosine is used as protective agent for many therapies. Ginkgo Biloba extract reduces oxidative damage and stimulates cell survival. While both these compounds are known to be administrated individually for their respective
mechanism of action, administration with immediate release has a limitation of multiple daily administration leading to fluctuating plasma concentrations.
Therefore, there is an urgent need for the improved controlled delivery therapy with pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract which can delivery either or both active ingredients in controlled manner.
Till date, pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one or both active ingredient are in controlled release form, are not known.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to pharmaceutical composition comprising L- Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract. The present invention relates to pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form. The present invention relates to a controlled release pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract. The active ingredient as per present invention are used in therapeutically effective amount.
“Therapeutically effective amount” or “effective amount” refers to the amount of a pharmaceutically active agent when administered, is sufficient to affect such prevention or treatment. The therapeutically effective amount will vary depending on the disease and its severity, and the age, weight, and other conditions of the patient to be treated.
The term “pharmaceutical compositions” herein refers to any composition for administration to human or animal by any route and includes but are not limited to delayed release, extended release and pulsed-release.
The term “immediate release” herein refers to any composition for administration to human or animal which releases active ingredient upon administration immediately.
The term “controlled release” herein refers to any composition for administration to human or animal which is not immediate release and includes extended release, delayed release and pulsatile release.
In an embodiment, the present invention relates to a pharmaceutical composition comprising a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
In an embodiment, the present invention relates to a pharmaceutical composition comprising a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form.
In an embodiment, the present invention relates to a pharmaceutical composition consisting of a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and
b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
In an embodiment, the present invention relates to a controlled release pharmaceutical composition comprising c. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and d. Ginkgo Biloba extract.
In an embodiment, the present invention relates to a controlled release pharmaceutical composition consisting of c. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and d. Ginkgo Biloba extract.
In a preferred embodiment, the present invention relates to a pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein at least one active ingredient is in controlled release form.
In a preferred embodiment, the present invention relates to a pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form.
In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein at least one active ingredient is in controlled release form.
In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition is a bilayer tablet.
In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition comprises comprises Hydroxy Propyl Methyl cellulose as extended release polymer.
In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition releases less than 90% L-Carnosine or pharmaceutically acceptable salts or derivatives thereof after 8 hours in 6.8 pH phosphate buffer.
In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in extended release form and wherein said composition is a bilayer tablet.
In a preferred embodiment, the present invention relates to a controlled release pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg.
In a preferred embodiment, the present invention relates to a controlled release oral pharmaceutical comprising
a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg.
In one or more embodiments, a pharmaceutical composition as per present invention includes delayed release, extended release, pulsatile release or combination thereof.
In one or more embodiments, a pharmaceutical composition as per present invention comprises active ingredients in homogenous mixture or physically separated compartments.
In one or more embodiments, a pharmaceutical composition as per present invention comprises L-Carnosine or pharmaceutically acceptable salts or derivatives thereof are in extended release form.
In one or more embodiments, a pharmaceutical composition as per present invention includes for oral, intravenous or other routes of administration.
In one or more embodiments, a pharmaceutical composition as per present invention includes solid, liquid, semisolid or other dosage forms.
In one or more embodiments, the present invention also relates to a process for preparation of a pharmaceutical composition wherein said process comprises step of a. Preparing granules of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof with at least one controlled release excipient, b. Preparing granules of Ginkgo Biloba extract, c. Processing granules of step (a) and step (b) into bilayer tablet.
In a preferred embodiments, a process as per present invention involves non aqueous solvent granulation.
L- Carnosine
Carnosine is an endogenous dipeptide, composed of b-alanine and L- histidine. Carnosine has pH-buffering, metal-ion chelation, and antioxidant capacity as well as the capacity to protect against formation of advanced glycation and lipoxidation end-products. Carnosine is found naturally mainly in the skeletal muscles, central nervous system, olfactory neurons and in the lens of the eye in some vertebrates, including humans.
It has been suggested that carnosine may be involved in the prevention and therapy of oxidative driven disorders, including neurodegenerative diseases and hypoxic-ischemic damage of CNS. Carnosine treatment has been reported to improve glucose metabolism as well as spatial recognition memory, retention and recall. It has also been reported to have pronounced neuroprotective action on Parkinson’s disease increasing efficiency of basic therapy and suppressing beta amyloid peptide toxicity in Alzheimer’s disease.
In one or more embodiments, L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in the equivalent therapeutically effective amount of L-Carnosine. In a preferred embodiment, L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in an amount equivalent to 50mg to 400mg of L-Camosine.
Ginkgo Biloba Extract
Ginkgo Biloba is the leaf extract primarily for China. It has antioxidant, anti-apoptotic, anti-ageing properties. In ancient and modem Chinese herbal
pharmacopoeia, it is indicated for treatment for heart and lung complications. In US and Europe, it is used for its protective effect on neuron in de-generative dementias of the Alzheimer type. Dementia is a chronic or progressive condition characterized by impaired cognitive capacity.
Ginkgo Biloba Extract mainly contains 22.0 - 27.0% flavonoids, calculated as flavonoid glycosides and terpenoids, terpenoids consisting of bilobalide and the ginkgolides (2.6 - 3.2% bilobalide and 2.8 - 3.4% ginkgolides A, B and C). Usually administered doses of Ginkgo Biloba extract is 120-240 mg/day divided into 2 or 3 doses with meals. It has time to peak plasma concentration (Tmax) of 1 to 2 hours and shorter plasma half-life of ginkgolide A (3 to 4 hours) and B (4 to 6 hours) and bilobalide (2 to 3 hours) with primary excreted in the urine unchanged. Multiple daily doses lead to non-uniform plasma levels of its content in the body.
In one or more embodiments, Ginkgo Biloba Extract is in an amount of 20 mg to 200 mg.
Pharmaceutical Composition
L-Carnosine is the antioxidant with neuroprotective effect through involvement in endogenous pathway. Gingko biloba extract is a herbal exogenous antiapoptotic agent with directly neuroprotective effect. The present invention relates to a pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form. The present invention relates to a controlled release pharmaceutical composition comprising L- Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
The pharmaceutical composition as per present invention contains Ginkgo Biloba extract and L-Carnosine in the ratio between 1:1 and 1:6. In one
embodiment, the pharmaceutical composition as per present invention contains Ginkgo Biloba extract and L-Camosine in an amount of 60mg;200mg, 90mg;300mg and 120mg; 400mg.
The pharmaceutical compositions are the different type of medicinal preparation designed for the administration of targeted one or more drugs. The pharmaceutical compositions as per present invention includes immediate release, delayed release, extended release and pulsed-release. The pharmaceutical compositions can be prepared using uniform mixture of two or more drugs. In one or more embodiments, pharmaceutical composition can be prepared with one or more drugs in separate compartment within a single dosage form. The pharmaceutical compositions as per present invention can be administered by oral, intravenous or other routes of drug administration. The pharmaceutical compositions as per present invention can be solid, liquid, semisolid or any other dosage form. The pharmaceutical compositions as per present invention can be prepared as one or more drug in modified release and other drugs as immediate release in single dosage form.
The oral pharmaceutical dosage form are tablets, capsules, suspensions, powders and granules, multi-particulate dosage forms and the likes. The multicompartment dosage form are bilayer tablets, capsule-in-capsule, tablet-in capsule and any other dosage form. The pharmaceutical compositions can be formulated by any techniques known to or appreciated by a person skilled in the art
The controlled release excipients as per present invention includes enteric polymer, sustained release polymers, natural polysaccharides, wax. The representative controlled release agents are hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, polyethylene glycol, sodium alginate and so on.
In an embodiment, the oral pharmaceutical composition further includes optionally any one or a combination of one or more pharmaceutically acceptable excipients, such as but not limited to carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants and solubility enhancers.
Having described the invention with reference to the different embodiments of the invention, other embodiments will become apparent to one skilled in the art from consideration of the specifications.
The innovation is further defined by reference to the following examples. It will be apparent to those skilled in the art that many modifications, both to the composition and treatment, may be practiced without departing from the scope of this invention.
EXAMPLE - 1
Representative tablet composition of L- Camosine and Ginkgo Biloba extract
EXAMPLE - 2
Representative capsule composition of L- Carnosine and Ginkgo Biloba extract
EXAMPLE - 3
Representative capsule composition of L- Carnosine and Ginkgo Biloba extract
EXAMPLE - 4
Each film coated bilayer tablet Contains: Ginkgo biloba 60 mg (as immediate release form) and L-Camosine 200 mg (as sustained release form)
L- Carnosine (SR) Layer:
Mix L-Carnosine, Hydroxy Propyl Methyl cellulose (K4-M), Microcrystalline Cellulose (PH-101) and Dicalcium Phosphate dihydrate into the RMG.
Add the Povidone IPA binder solution slowly in to RMG to get uniform granulated mass. Sift the semi dried granules and dried granules through 20# mesh sieve and collect into a poly bag.
Sift Hydroxy Propyl Methyl cellulose (K-100), Colloidal Silicon di oxide, Croscarmellose sodium and Sodium stearyl fumarate through 40# mesh sieve and collect into a poly bag
Transfer the 20# mesh sifted dried granules into the blender and add the total sifted (40 # mesh) quantity of Hydroxy Propyl Methyl cellulose (K-100), Colloidal Silicon di oxide, Croscarmellose sodium and Sodium stearyl fumarate into the blender and mix for 15min at 10 RPM.
Sift total dispensed quantity of Magnesium stearate through 40# mesh sieve and transfer into the above blender and mix for 5min at 10 RPM.
Collect the sifted dried granules in poly bags.
Ginkgo Biloba Layer:
Sift Ginkgo Biloba Extract, Microcrystalline cellulose (PH -102), Crospovidone (XL- 10) through 40# mesh sieve and collect into a poly bag and transfer the sifted dry mix part into the RMG and mix for 15min with impeller at slow speed and Chopper off.
Add the Povidone IPA binder solution slowly in to RMG to get uniform granulated mass.
Dry the above wet mass. Sift the semi dried granules and dried granules through 20# mesh sieve and collect into a poly bag.
Sift Crospovidone (XL- 10, Colloidal Silicon di oxide, Polacrilin Potassium and Sodium stearyl fumarate through 40# mesh sieve and collect into a poly bag Transfer the 20# mesh dried sifted granules into the blender and add the total sifted (40 # mesh) quantity of Crospovidone (XL- 10), Colloidal Silicon di oxide, Polacrilin Potassium and Sodium stearyl fumarate into the blender and mix for 15min at 10 RPM.
Sift total dispensed quantity of Magnesium stearate through 40# mesh sieve and transfer into the above blender and mix for 5min at 10 RPM.
Collect the sifted dried granules in a poly bags and labeled with product identity.
Compression and Coating
The above lubricated blend (L- Carnosine (SR) Layer and Ginkgo Biloba Layer) compressed using caplet shaped, slightly biconvex with break line on one side and plain on another side punch. The compressed tablets are coated with Insta sol.
Dissolution for L-Carnosine using 6.8 pH phosphate buffer. (USP 2; Volume 900ml, 50RPM)
Claims
1. A pharmaceutical composition comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
2. The pharmaceutical composition according to the claim 1, wherein said composition comprises a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg
3. The pharmaceutical composition according to the claim 1, wherein said composition comprises L-Carnosine or pharmaceutically acceptable salts or derivatives thereof are in controlled release form.
4. The pharmaceutical composition according to the claim 3, wherein said controlled release form is extended release form.
5. The pharmaceutical composition according to the claim 1, wherein said composition is a bilayer tablet.
6. The pharmaceutical composition according to the claim 4, wherein said extended release form further comprises Hydroxy Propyl Methyl cellulose as extended release polymer.
7. The pharmaceutical composition according to the claim 1, wherein said composition is oral dosage form.
8. The pharmaceutical composition according to the claim 1, wherein said composition releases less than 90% L-Camosine or pharmaceutically acceptable salts or derivatives thereof after 8 hours in pH 6.8 phosphate buffer.
9. A process for preparation of a pharmaceutical composition wherein said process comprises step of
a. Preparing granules of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof with at least one controlled release excipient, b. Preparing granules of Ginkgo Biloba extract, c. Processing granules of step (a) and step (b) into bilayer tablet.
10. The process according to claim 1, wherein said granules are prepared using non aqueous solvent granulation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021027027 | 2020-06-25 | ||
| IN202021027027 | 2020-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021260636A1 true WO2021260636A1 (en) | 2021-12-30 |
Family
ID=79282177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2021/055647 WO2021260636A1 (en) | 2020-06-25 | 2021-06-25 | A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021260636A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259150A (en) * | 2008-04-22 | 2008-09-10 | 复旦大学 | Sustained-release pellet of ginkgo biloba extract and its preparation |
| WO2012146592A1 (en) * | 2011-04-27 | 2012-11-01 | Dr. Willmar Schwabe Gmbh & Co. Kg | Controlled release tablet of ginkgo biloba extract and procedure for obtaining it |
-
2021
- 2021-06-25 WO PCT/IB2021/055647 patent/WO2021260636A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259150A (en) * | 2008-04-22 | 2008-09-10 | 复旦大学 | Sustained-release pellet of ginkgo biloba extract and its preparation |
| WO2012146592A1 (en) * | 2011-04-27 | 2012-11-01 | Dr. Willmar Schwabe Gmbh & Co. Kg | Controlled release tablet of ginkgo biloba extract and procedure for obtaining it |
Non-Patent Citations (2)
| Title |
|---|
| "Kobacar tablet", SEPTALYST, 11 July 2019 (2019-07-11) * |
| CUI Q ET AL.: "Preparation and in vitro release of Ginkgo biloba extract sustained-release tablets", ZHONGGUO ZHONG YAO ZA ZHI, vol. 34, no. 15, 8 January 2009 (2009-01-08), pages 1910 - 13 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190290626A1 (en) | Method of treatment with tradipitant | |
| US11318144B2 (en) | Compositions and methods for treating Alzheimer's disease and Parkinson's disease | |
| JP7083835B2 (en) | Zinc-γ-PGA composition and methods for treating cancer | |
| CA3183560A1 (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
| JPH0635382B2 (en) | Uses of fluoxetine as an anxiolytic | |
| US20060246133A1 (en) | Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same | |
| IL272834B1 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| US11376267B2 (en) | Drug combination for treatment of amyotrophic lateral sclerosis, preparation method and use thereof | |
| US20080206348A1 (en) | Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers | |
| AU2014326142B2 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| WO2021260636A1 (en) | A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract | |
| US7867524B2 (en) | Energizing formulation | |
| KR20190014512A (en) | Small-sized Melatonin Tablets and Manufacturing Method Thereof | |
| RU2336076C2 (en) | Peroral medical product for offset of magnesium deficiency in organism | |
| KR101978459B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| WO2017029225A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| JP2003095981A (en) | Medicine composition | |
| US11179377B2 (en) | Pharmaceutical compositions and uses thereof | |
| US20130143912A1 (en) | Sublingual zolpidem formulations | |
| US20210052608A1 (en) | Methods of treating bacterial infections with minocycline | |
| US20240082176A1 (en) | Dropropizine in combination with ambroxol in the dosage form of syrup and tablets | |
| WO2023240092A1 (en) | Ebselen containing oral dosage forms | |
| KR20170000907A (en) | Pharmaceutical composition comprising the isopropanol extract of artemisia | |
| KR20150063040A (en) | Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations | |
| TR202019859A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING EMOXIPIN AND DONEPEZIL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21827995 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21827995 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21827995 Country of ref document: EP Kind code of ref document: A1 |